Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy

por Penny, Hweixian Leong, Hainline, Kelly, Theoharis, Nathaniel, Wu, Bin, Brandl, Christian, Webhofer, Christian, McComb, Mason, Wittemer-Rump, Sabine, Koca, Gökben, Stienen, Sabine, Bargou, Ralf C., Hummel, Horst-Dieter, Loidl, Wolfgang, Grüllich, Carsten, Eggert, Tobias, Tran, Ben, Mytych, Daniel T.
Publicado 2023